A UK biotech company seeks clinical, academic, or industry R&D and investment partners to co-develop a dual A2AR/mGlu5R inhibitor (HT8457) for glioblastoma.

Summary

Profile type

Technology offer

Company's country

United Kingdom

POD reference

TOGB20250908008

Profile status

PUBLISHED

Type of partnership

Research and development cooperation agreement

Investment agreement

Targeted countries

- **Canada**
- **Australia**
- **Latvia**
- **Austria**
- **Lithuania**
- **Hungary**
- **Romania**
- **Greece**
- **Estonia**
- **France**
- **Ireland**
- **Sweden**
- **Finland**
- **Belgium**
- **Portugal**
- **Germany**
- **Denmark**
- **United Kingdom**
- **Slovenia**
- **Slovakia**
- **Italy**

- **Bulgaria**
- **Cyprus**
- **Spain**
- **Netherlands**
- **Poland**
- **Croatia**
- **United States**
- **Japan**
- **Luxembourg**
- **Malta**

Contact Person	Term of validity	Last update
Enrico FRANZIN	**8 Sep 2025** **8 Sep 2026**	**8 Sep 2025**

General Information

Short summary

Hado Therapeutics (UK) develops dual- and multi-target small molecule inhibitors aimed at improving clinical outcomes. Their high-hit-rate screening platform significantly reduces discovery time and cost. The company offers HT8457, a novel dual A2A/mGlu5 receptor inhibitor for glioblastoma and is actively seeking R&D and investment partners to accelerate pre-clinical validation, IND-enabling studies, and early-phase clinical trials toward proof-of-concept.

Full description

Hado Therapeutics discover pioneering medicines for diseases ranging from rare disorders to indications of significant disease burden. Hado discovered first-in-class compounds for treating glioblastoma, Parkinson's disease, diabetic neuropathy and bleeding disorders. Their immuno-oncology project aims to develop a first-in-class small molecule that enhances anti-tumour immunity with tumour-destroying ability, thus eliminating tumour burden. This novel and powerful approach counters cancer resistance and is an attractive treatment option for cancer patients who do not respond to existing therapy.

Glioblastoma is the most aggressive and most common type of cancer that originates in the brain and affects over 300,000 people globally each year, with a median survival of 12–15 months. With no curative treatment and a high relapse rate, there is intense market pull for novel CNS (Central Nervous System) penetrant therapies. HT8457 offers partners the opportunity to co-develop a first-in-class therapy with global market potential, supported by robust preclinical data and a clear regulatory pathway.
Scientific basis:

- HT8457 binds to A2AR and mGlu5R in cell-based models.
- Inhibits NECA-induced (5′-N-ethyl-carboxamidoadenosine) cAMP (Cyclic Adenosine Monophosphate)

response (IC_{50} = 8.29 µM) and L-glutamate-induced calcium response (IC_{50} = 5.11 µM), benchmarked against known selective antagonists (ZM241385 for A2AR (Adenosine A2A Receptor), AZD 9272 for mGlu5R).

The underlying science behind dual-target approaches in cancer therapy is well established; however, their specific choice of targets is novel and represents the distinctive element of the strategy. This information is now publicly available to inform investors and strategic partners.

Rationale: Dual inhibition of A2AR and mGlu5R is hypothesised to enhance anti-tumour immune responses and disrupt tumour–microglia signalling, potentially improving GBM (Glioblastoma Multiforme) treatment outcomes beyond current monotherapies. Past failures target either immune suppression or tumour signalling. The company targets both. This combined approach (double tap) reduces escape mechanisms.

Development needs: Following promising in vitro data, they aim to:
- Validate functional synergy between A2AR and mGlu5R antagonism in GBM models.
- Expand the chemical series with potent, selective analogues.
- Advance candidates into IND (Investigational New Drug) enabling and early-phase clinical studies.

Cooperation sought: They seek partners for research cooperation agreement and investment agreement with expertise in:
- Preclinical pharmacology and regulatory submissions.
- Access to GBM patient cohorts.
- Medicinal chemistry and CNS (Central Nervous System) drug delivery optimisation.
- Neuro-oncology clinical trials (Phase I/II).

Advantages and innovations

A. Rapid, low-cost discovery using proprietary high-hit-rate platform — reduces R&D timelines and risk for partners.
B. First-in-class dual-target therapy for glioblastoma (A2AR + mGlu5R).
C. Proven target functional activity in multiple assays.
D. Potential to overcome drug resistance to temozolomide and radiotherapy.
E. Oral administration with blood–brain barrier penetration potential.
F. Biomarker-driven precision medicine approach.
G. Expertise in repurposing molecules and natural products for new oncology targets.

Technical specification or expertise sought

Stage of development

Lab tested

Sustainable Development goals

- **Goal 9: Industry, Innovation and Infrastructure**
- **Goal 3: Good Health and Well-being**

IPR Status

No IPR applied

IPR Notes

Partner Sought

Expected role of the partner

Partners will co-develop HT8457 from preclinical optimisation to early clinical trials, contribute to regulatory and clinical strategy, lead or support patient recruitment, and collaborate on biomarker-led patient selection. They are open to joint IP development, regional licensing, and revenue-sharing agreements.

They invite academic, clinical, and industry partners to discuss collaboration structures that align with mutual objectives and accelerate HT8457's path to patients.

Type of partnership

Research and development cooperation agreement

Investment agreement

Type and size of the partner

- **SME 11-49**
- **University**
- **R&D Institution**
- **SME <=10**
- **SME 50 - 249**
- **Other**
- **Big company**

Dissemination

Technology keywords

- **06001015 - Pharmaceutical Products / Drugs**
- **06001014 - Neurology, Brain Research**

Market keywords

- **05005014 - Oncology**

Targeted countries

- **Canada**
- **Australia**
- **Latvia**
- **Austria**
- **Lithuania**
- **Hungary**
- **Romania**
- **Greece**
- **Estonia**
- **France**
- **Ireland**
- **Sweden**
- **Finland**
- **Belgium**
- **Portugal**
- **Germany**
- **Denmark**
- **United Kingdom**
- **Slovenia**
- **Slovakia**
- **Italy**
- **Bulgaria**
- **Cyprus**
- **Spain**
- **Netherlands**
- **Poland**
- **Croatia**
- **United States**
- **Japan**
- **Luxembourg**

Sector groups involved

- **Health**

- **Malta**

Media

Images

Picture2a.png